su011248
Kidney Diseases
AstraZenecaPhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Kidney Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
nc-503 Bellus Health Inc. - a GSK company | Phase 2/3 | B |
VOLITINIB AstraZeneca | Phase 3 | B |
SEVELAMER Genzyme, a Sanofi Company | Phase 3 | B |
NKT2152 NiKang Therapeutics, Inc. | Phase 2 | CCC |
Palbociclib NiKang Therapeutics, Inc. | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →